Format

Send to

Choose Destination
See comment in PubMed Commons below
Nephrol Ther. 2008 Oct;4 Suppl 3:S170-3. doi: 10.1016/S1769-7255(08)74229-9.

[Immunosuppressor treatment in kidney transplantation from a live donor].

[Article in French]

Author information

  • 1Service de Néphrologie et d'Immunologie Clinique, CHU de Nantes, France. maryvonne.hourmant@chu-nantes.fr

Abstract

Live-donor transplantations have features that can influence the posttransplantation immunosuppressor treatment: a good-quality kidney and good transplantation conditions, which allow immediate return to kidney function with a high glomerular filtration rate and a lower risk of acute rejection. Very few studies have specifically evaluated the immunosuppressor treatment in the receiver of a kidney from a live donor and many questions remain unanswered. Nevertheless, according to clinical experience, it seems reasonable to use an induction treatment of IL-2 receptor monoclonal antibodies in the receivers of live-donor kidneys (with the exception of HLA-identical transplantations) whether or not the two are related. As for maintenance treatment, it seems important to preserve the number of nephrons in the graft using proliferation signal inhibitors instead of anticalcineurins. On the other hand, for transplantations where the donor and receiver are HLA-identical, it is more difficult to make recommendations because of many unanswered questions, which will remain so as long as specific randomized trials are not conducted.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk